eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | barrett esophagus |
| Comorbidity | C0001418|adenocarcinoma |
| Sentences | 53 |
| PubMedID- 24681073 | Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with barrett's esophagus. |
| PubMedID- 21820152 | The findings of this study improve our understanding of the role that chromosomal instability and alterations of tumor suppressor genes such as cdkn2a and oncogenes such as erbb2 play in the progression of intestinal metaplasia to adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 22353776 | Observational data have also indicated that statins may have protective effects against the development of cancer, for example, modifying the risk of oesophageal adenocarcinoma in patients with existing barrett's oesophagus [20]. |
| PubMedID- 20188100 | However, the possible effect these medications may have on the risk of esophageal adenocarcinoma (eac) in patients with existing barrett's esophagus (be) is unclear. |
| PubMedID- 23111465 | While some studies suggest ppis result in a significant reduction in the risk of developing dysplasia and adenocarcinoma in patients with barrett's esophagus, others suggest that ppis have no effect. |
| PubMedID- 23453294 | Patients: we studied 23 consecutive patients who underwent complete cesd for superficial esophageal carcinoma (22 squamous cell carcinomas and 1 adenocarcinoma associated with barrett's esophagus). |
| PubMedID- 23617676 | We report herein a case of adenocarcinoma arising from short-segment barrett's esophagus (ssbe) in a 36-year-old man. |
| PubMedID- 25708344 | Oesophagectomy is a safe option for early adenocarcinoma arising from barrett's oesophagus. |
| PubMedID- 22302717 | There is a critical need to identify molecular markers that can reliably aid in stratifying esophageal adenocarcinoma (eac) risk in patients with barrett's esophagus. |
| PubMedID- 20937048 | Aim: to assess the effect of 40 mg twice daily esomeprazole (high-dose) on gastric and oesophageal ph and symptoms, and biomarkers relevant to adenocarcinoma, in patients with barrett's oesophagus (bo). |
| PubMedID- 21115135 | The incidence of esophageal adenocarcinoma among patients with nondysplastic barrett's esophagus has been overestimated. |
| PubMedID- 22219077 | [risk of adenocarcinoma in patients with barrett esophagus is significantly less than previously assumed]. |
| PubMedID- 22443641 | Previously, the risk of progression to esophageal adenocarcinoma in patients with barrett's esophagus was thought to be approximately 1%. |
| PubMedID- 24221456 | Background and aims: acid-suppressive medications, particularly proton pump inhibitors (ppis), may decrease the risk of oesophageal adenocarcinoma (oac) in patients with barrett's oesophagus (bo). |
| PubMedID- 20610142 | In contrast to adenocarcinoma arising from barrett's esophagus in western countries, the major disease phenotype in the asia-pacific region is esophageal squamous cell carcinoma which is attributed to the prevalence of smoking, alcohol, and betel quid chewing. |
| PubMedID- 24765592 | In this present study by qumseya et al.,13 among 136 patients with adenocarcinoma or dysplasia of barrett's esophagus, 27% had esophageal stricture. |
| PubMedID- 22241250 | Use of statin medications and risk of esophageal adenocarcinoma in persons with barrett's esophagus. |
| PubMedID- 25843080 | Acid-suppressive medications and risk of esophageal adenocarcinoma in patients with barrett's esophagus(gut 2014;63:1229-1237). |
| PubMedID- 21143918 | There are few clear prognostic indicators of susceptibility to developing oesophageal adenocarcinoma although patients with barrett's oesophagus are thought to be more at risk to developing oesophageal adenocarcinoma. |
| PubMedID- 23243384 | For upper gi tract pathology i-scan assisted in diagnosis or therapy of barrett's esophagus with dysplasia, esophageal adenocarcinoma, hsv esophagitis, gastric malt lymphoma, gastric antral intestinal metaplasia with dysplasia, duodenal follicular lymphoma, and a flat duodenal adenoma. |
| PubMedID- 24737143 | Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 20397052 | Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 26233550 | Serum 25-hydroxyvitamin d levels and the risk of dysplasia and esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 21375764 | In contrast with the esophageal adenocarcinoma arising from barrett's esophagus in western countries, the major phenotype in the asia-pacific region is esophageal squamous cell carcinoma (escc) [2,3]. |
| PubMedID- 24212953 | Epidemiologic studies showed that long-term use of ppi was associated with lower rates of dysplasia and adenocarcinoma in patients with barrett's esophagus [24,25]. |
| PubMedID- 20698040 | The annual incidence of adenocarcinoma arising from barrett's esophagus (be) is approximately 0.5%. |
| PubMedID- 25621687 | The incidence of esophageal adenocarcinoma arising from barrett esophagus (be) has been rapidly increasing in many western countries over the past few decades.1–3 it also leads to increasing the rate of hospitalization for esophageal adenocarcinoma and causes a serious problem.4 endoscopic surveillance of be, the currently accepted standard, aims to reduce morbidity and mortality by early detection and endoscopic therapy of dysplasia or cancer.5–8 current guidelines from gastroenterology societies recommend endoscopic surveillance of be using white light endoscopy (wle) with targeted biopsies of any endoscopically visible lesions and 4 random quadrant biopsies from every 2 cm of the be segment (seattle protocol).7,9 however, it has been pointed out that this protocol has several limitations, such as time required, low compliance, and increased risk of sampling error.10 therefore, establishment of a more effective surveillance program for detecting dysplastic lesions or those with high malignant potential in be patients is highly desirable. |
| PubMedID- 24605249 | Observational studies have shown that non-steroidal anti-inflammatory drugs could reduce the adenocarcinoma incidence in patients with barrett's esophagus by 41%, while statins could reduce the risk by 43%. |
| PubMedID- 23591735 | We suggest that it may be useful to stratify the risk of adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 26311716 | Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with barrett's oesophagus. |
| PubMedID- 24968432 | Pathological diagnosis was adenocarcinoma with barrett's esophagus. |
| PubMedID- 25071359 | Lifetime risk of esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 22626608 | Background & aims: radiofrequency ablation (rfa) reduces the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be) with high-grade dysplasia (hgd), but its effects in patients without dysplasia are debatable. |
| PubMedID- 22796132 | Background& aims: proton pump inhibitors and nonsteroidal anti-inflammatory drugs might prevent esophageal adenocarcinoma in patients with barrett's esophagus (be), but there are limited data from clinical trials to support this concept. |
| PubMedID- 26208896 | Background & aims: statins have been reported to protect against esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be). |
| PubMedID- 24570878 | As exemplified in esophageal adenocarcinoma, the early detection of barrett esophagus (be) with low- or high-grade dysplasia (hgd) might represent the most attractive goal to achieve a cure. |
| PubMedID- 23617672 | It is often difficult to accurately delineate the borders and extent of early-stage esophageal adenocarcinoma in patients with barrett's esophagus using conventional white light endoscopy. |
| PubMedID- 20550712 | The 'exercise and the prevention of oesophageal cancer study' will determine whether 24 weeks of exercise training will lead to alterations in risk factors or biomarkers for oesophageal adenocarcinoma in males with barrett's oesophagus. |
| PubMedID- 26202380 | Overexpression of cd55 from barrett's esophagus is associated with esophageal adenocarcinoma risk. |
| PubMedID- 24570884 | In the united states, the burden of esophageal cancer in 2007 was 16,640 new cases and 14,500 deaths with a 5-year survival rate of only 15%.1 of these cases, 65% were adenocarcinoma associated with barrett esophagus (be). |
| PubMedID- 26068095 | We explored next-generation sequencing to detect mutations with the analytical sensitivity required to predict concurrent high-grade dysplasia (hgd) and esophageal adenocarcinoma (eac) in patients with barrett's esophagus by testing nonneoplastic bim. |
| PubMedID- 21593708 | Incidence of esophageal adenocarcinoma with barrett esophagus (be) imposes a decision about therapy management. |
| PubMedID- 21309910 | Dysplasia and esophageal adenocarcinoma may arise in patients with barrett's esophagus after fundoplication esophageal ph monitoring showing no acid in esophagus. |
| PubMedID- 19660251 | Rapid progression of barrett's esophagus into adenocarcinoma in a combined lung and kidney transplant recipient. |
| PubMedID- 21995385 | Incidence of adenocarcinoma among patients with barrett's esophagus. |
| PubMedID- 24651385 | Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with barrett's esophagus: a meta-analysis. |
| PubMedID- 23714382 | Background & aims: recent population-based studies have shown a low risk of esophageal adenocarcinoma (eac) in patients with nondysplastic barrett's esophagus (ndbe). |
| PubMedID- 26426603 | Cost-effectiveness decision tree model of endoscopic surveillance for esophageal adenocarcinoma among patients with definite barrett's esophagus. |
| PubMedID- 23338150 | Therefore, telomerase inhibitors may exhibit high potency in the treatment of esophageal adenocarcinoma arising from barrett's esophagus. |
| PubMedID- 21857838 | barrett esophagus with progression to adenocarcinoma in multiple family members with attenuated familial polyposis. |
Page: 1 2